Narcolepsy - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 59 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Narcolepsy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Narcolepsy - Pipeline Review, H2 2014', provides an overview of the Narcolepsy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Narcolepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Narcolepsy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Narcolepsy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Narcolepsy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Narcolepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Narcolepsy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Narcolepsy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Narcolepsy Overview 7
Therapeutics Development 8
Pipeline Products for Narcolepsy - Overview 8
Pipeline Products for Narcolepsy - Comparative Analysis 9
Narcolepsy - Therapeutics under Development by Companies 10
Narcolepsy - Therapeutics under Investigation by Universities/Institutes 12
Narcolepsy - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Narcolepsy - Products under Development by Companies 16
Narcolepsy - Products under Investigation by Universities/Institutes 17
Narcolepsy - Companies Involved in Therapeutics Development 18
Taisho Pharmaceutical Co., Ltd. 18
Evotec AG 19
Jazz Pharmaceuticals plc 20
Flamel Technologies S.A. 21
Grupo Ferrer Internacional, S.A. 22
Concert Pharmaceuticals, Inc. 23
BIOPROJET SCR 24
SK Biopharmaceuticals Co., Ltd. 25
Spherium biomed S.L. 26
Narcolepsy - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 33
Drug Profiles 34
tiprolisant - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SKL-N05 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TS-091 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
JZP-386 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
sodium oxybate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
EVT-501 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
arbaclofen - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SP-14002 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
C-10291 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Drugs to Target Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules to Agonize Orexin Receptor for Narcolepsy and EDS - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Narcolepsy - Recent Pipeline Updates 48
Narcolepsy - Dormant Projects 50
Narcolepsy - Discontinued Products 51
Narcolepsy - Product Development Milestones 52
Featured News & Press Releases 52
Jul 21, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 52
Jun 02, 2014: Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 52
May 27, 2014: Jazz Pharmaceuticals To Present Data On Compound In Sleep Pipeline During APSS Annual SLEEP Meeting 53
Apr 07, 2014: Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate 53
Jun 03, 2013: Aerial BioPharma Announces Presentation Of ADX-NO5 Results At SLEEP 2013 Meeting 54
Dec 17, 2012: FDA Announces Combined Use Of Jazz Pharma's Xyrem With Alcohol Or CNS Depressants May Lead To Respiratory Depression 55
Dec 04, 2012: Jazz Pharma Obtains Additional Xyrem Patent From USPTO 55
Sep 11, 2012: Jazz Pharma Announces Issuance Of New Formulation Patent For Xyrem 56
Aug 29, 2012: Aerial BioPharma Receives FDA Orphan Drug Designation For Narcolepsy Drug In Development 56
Aug 10, 2012: Mylan Launches Generic Provigil Tablets 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products under Development for Narcolepsy, H2 2014 8
Number of Products under Development for Narcolepsy - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Narcolepsy - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 18
Narcolepsy - Pipeline by Evotec AG, H2 2014 19
Narcolepsy - Pipeline by Jazz Pharmaceuticals plc, H2 2014 20
Narcolepsy - Pipeline by Flamel Technologies S.A., H2 2014 21
Narcolepsy - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 22
Narcolepsy - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 23
Narcolepsy - Pipeline by BIOPROJET SCR, H2 2014 24
Narcolepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 25
Narcolepsy - Pipeline by Spherium biomed S.L., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 33
Narcolepsy Therapeutics - Recent Pipeline Updates, H2 2014 48
Narcolepsy - Dormant Projects, H2 2014 50
Narcolepsy - Discontinued Products, H2 2014 51